- Citations, last 5 years
- 100
- Works, last 5 years
- 28
- h-index
- 49
- Scientists listed
- 4
- Grants since 2016
- 12
Grants received
2024–2026 · research · R44
Development of an antibody-oligonucleotide conjugate for treatment of Head and Neck Squamous Cell Carcinoma
Anthony D Saleh · Ashland (United States) · funded by National Institutes of Health
2024–2026 · research · R44
Development of an antibody-oligonucleotide conjugate for treatment of Head and Neck Squamous Cell Carcinoma
Anthony D Saleh · Ashland (United States) · funded by National Institutes of Health
2021–2023 · research · R44
A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders
Anthony D Saleh · Ashland (United States) · funded by National Institutes of Health
2021–2024 · research · R44
A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders
Anthony D Saleh · Ashland (United States) · funded by National Institutes of Health
2021–2027 · research · R44
A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders
Anthony D Saleh · Ashland (United States) · funded by National Institutes of Health
2021–2027 · research · R44
A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders
Anthony D Saleh · Ashland (United States) · funded by National Institutes of Health
2018 · cooperative agreement · U43
A Novel Targeted Nanomedicine Delivering MicroRNA-30-5p Replacement
Esther H Chang · Ashland (United States) · funded by National Institutes of Health
2018–2019 · contract · N01
Development of a CXCR4 Targeted miR-29b-3p microRNA Mimic to Treat HIV
Anthony Saleh · Ashland (United States) · funded by National Institutes of Health
2017–2019 · cooperative agreement · U43
A Novel Targeted Nanomedicine Delivering MicroRNA-30-5p Replacement Therapy for Multi-drug Resistant Cancer Treatment
Esther H Chang · Ashland (United States) · funded by National Institutes of Health
2017–2019 · cooperative agreement · U43
A Novel Targeted Nanomedicine Delivering MicroRNA-30-5p Replacement Therapy for Multi-drug Resistant Cancer Treatment
Esther H Chang · Ashland (United States) · funded by National Institutes of Health
2017–2022 · cooperative agreement · U44
Novel Targeted Nanomedicine Delivering MicroRNA-30-5p ReplacementTherapy for Multi-drug Resistant Cancer Treatment
Robert F Place · Ashland (United States) · funded by National Institutes of Health
2017–2023 · cooperative agreement · U44
Novel Targeted Nanomedicine Delivering MicroRNA-30-5p ReplacementTherapy for Multi-drug Resistant Cancer Treatment
Anthony D Saleh · Ashland (United States) · funded by National Institutes of Health